Rituxim

100 mg

500 mg

Generic Name: Rituximab

Product Description:
Rituxim IV Infusion contains Rituximab, a chimeric monoclonal antibody that targets the CD20 antigen found on the surface of normal and malignant B lymphocytes. By binding to CD20, Rituximab induces B-cell lysis through complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and apoptosis.

Available Strengths:

• Rituximab 100 mg/10 ml vial

• Rituximab 500 mg/50 ml vial

Dosage Form: Concentrate for solution for intravenous infusion.
Concentration: 10 mg/ml

Indications:

• Non-Hodgkin’s lymphoma (NHL)

• Chronic lymphocytic leukemia (CLL)

• Rheumatoid arthritis (in combination with methotrexate)

• Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)

• Other CD20-positive B-cell malignancies and certain autoimmune diseases (as approved by regulatory authorities)

Packaging:
Single-dose vial in sterile form for dilution and IV administration.